All JYNNEOS articles
-
NewsLower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen
A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks (two weeks after the second dose), according to new findings.
-
NewsCase report shows mpox breakthrough infection in man who had received both vaccine doses
New research details the case of a man who had received two doses of the monkey pox vaccine in Autumn, 2022 yet experienced a ‘breakthrough’ mpox infection in January 2024.
-
NewsStudy shows Mpox (monkeypox) antibodies wane within a year of vaccination
New research shows that the antibodies produced by Modified Vaccinia virus Ankara - Bavarian Nordic (MVA-BN) vaccination against mpox wane significantly within a year of receiving the vaccination.
-
NewsScientists report positive immune response against mpox using a vaccine
Scientists at one of the largest cancer research and treatment organizations in the United States show that its COVID-19 vaccine also protects against mpox.
-
NewsSmallpox vaccine induces immunity against monkeypox infection in people living with HIV
Researchers have shown that intradermal vaccination with the JYNNEOS vaccine against smallpox is the best option to protect people living with HIV from contracting the monkeypox virus.
-
NewsMpox vaccine triggers equally strong immune response in smaller doses
Delivering the two-dose mpox vaccine in smaller than the usual FDA-approved doses produced a detectable immune response. This also occurred regardless of whether people were living with or without HIV.
